94 related articles for article (PubMed ID: 21734413)
21. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
22. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
23. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
24. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.
Hicks DG; Short SM; Prescott NL; Tarr SM; Coleman KA; Yoder BJ; Crowe JP; Choueiri TK; Dawson AE; Budd GT; Tubbs RR; Casey G; Weil RJ
Am J Surg Pathol; 2006 Sep; 30(9):1097-104. PubMed ID: 16931954
[TBL] [Abstract][Full Text] [Related]
25. Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis.
Na IK; Scheibenbogen C; Adam C; Stroux A; Ghadjar P; Thiel E; Keilholz U; Coupland SE
Hum Pathol; 2008 Dec; 39(12):1751-5. PubMed ID: 18701133
[TBL] [Abstract][Full Text] [Related]
26. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
27. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.
Kaifi JT; Yekebas EF; Schurr P; Obonyo D; Wachowiak R; Busch P; Heinecke A; Pantel K; Izbicki JR
J Natl Cancer Inst; 2005 Dec; 97(24):1840-7. PubMed ID: 16368946
[TBL] [Abstract][Full Text] [Related]
28. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer.
Huang EH; Singh B; Cristofanilli M; Gelovani J; Wei C; Vincent L; Cook KR; Lucci A
J Surg Res; 2009 Aug; 155(2):231-6. PubMed ID: 19482312
[TBL] [Abstract][Full Text] [Related]
29. Pattern of metastatic spread in triple-negative breast cancer.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
[TBL] [Abstract][Full Text] [Related]
30. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies.
Amir E; Ooi WS; Simmons C; Kahn H; Christakis M; Popovic S; Kalina M; Chesney A; Singh G; Clemons M
Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):763-8. PubMed ID: 18824337
[TBL] [Abstract][Full Text] [Related]
31. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
Ling LJ; Wang S; Liu XA; Shen EC; Ding Q; Lu C; Xu J; Cao QH; Zhu HQ; Wang F
Chin Med J (Engl); 2008 Oct; 121(20):1980-6. PubMed ID: 19080260
[TBL] [Abstract][Full Text] [Related]
32. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
[TBL] [Abstract][Full Text] [Related]
33. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival.
Mirisola V; Zuccarino A; Bachmeier BE; Sormani MP; Falter J; Nerlich A; Pfeffer U
Eur J Cancer; 2009 Sep; 45(14):2579-87. PubMed ID: 19646861
[TBL] [Abstract][Full Text] [Related]
34. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
[TBL] [Abstract][Full Text] [Related]
35. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Inoue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2010 Aug; 17(8):2051-8. PubMed ID: 20177796
[TBL] [Abstract][Full Text] [Related]
36. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
38. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers.
Waltregny D; Bellahcène A; de Leval X; Florkin B; Weidle U; Castronovo V
J Bone Miner Res; 2000 May; 15(5):834-43. PubMed ID: 10804012
[TBL] [Abstract][Full Text] [Related]
39. [Chemokine receptor CXCR4 gene silencing with shRNA inhibits breast cancer metastasis to the lung in nude mice].
Zhang MX; Han N; Yu SY; Leng Y
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):325-9. PubMed ID: 18953828
[TBL] [Abstract][Full Text] [Related]
40. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
